Buy or sell Samumed stock pre IPO via an EquityZen fund
EquityZen is a marketplace for shares of proven pre IPO tech companies
Samumed Stock
Medical Research & Development
About Samumed Stock
Samumed is in the medical research and development for tissue-level regeneration. With their platform's origins in small molecule-based Wnt pathway modulation, they develop therapeutics to address a range of degenerative diseases, regenerative medicine and oncology. Samumed adopted a fresh operating philosophy from the beginning — one based on a goal of building a broad technology platform aimed at modulating regenerative pathways to improve patient health.
Investors
Funding History
| September 2013 | $220M |
|---|---|
| August 2018 | $438M |
Management
Chief Executive Officer
Osman Kibar
Chief Medical Officer
Yusuf Yazici
Chief Information Officer
Blake Mobley
Chief Scientific Officer
Michael White
Press
Globe Newswire - Jun, 1 2020
Intrado - Oct, 2 2019
Intrado - Jul, 18 2019
Intrado - May, 2 2019
Globe Newswire - Feb, 28 2019
Other Companies
EquityZen does not have an affiliation with, formal relationship with, or endorsement from Samumed or any companies feature above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
